#EXP00001

General

Accession EXP00001
Activity Formation (3-24h)
Date 2013-11-08
Administration In solution
Model in vitro
Organism Staphylococcus aureus
Status Validated
Notes Sa4 clinical isolate

Peptide

SMAP-29

RGLRRLGRKIAHGVKKYGPTVLRIIRIA

Experimental activity

Method Concentration Notes
Crystal violet assay 0.626 uM No notes

References

Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients

A. Pompilio, M. Scocchi, S. Pomponio, F. Guida, A. Di Primio, E. Fiscarelli, R. Gennaro, G. Di Bonaventura

2011. Peptides 9:1807-1814